Physician profile
Donovan Polack
NPI 1659324465
$4,864.01
in general payments reported to CMS, 2019-2025
27 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $399 · 2021: $507 · 2022: $361 · 2023: $234 · 2024: $1,020 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $6.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.10 |
| Education | $6.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $588.36 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $517.70 | 2019-2024 | Velphoro, Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $480.85 | 2019-2025 | Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals Lp | $434.40 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $367.76 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $281.46 | 2019 | |
| Calliditas Therapeutics US INC. | $268.32 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $264.56 | 2020-2025 | Filspari |
| Nxstage Medical, INC. | $247.34 | 2019-2024 | |
| Opko Pharmaceuticals, LLC | $225.47 | 2020-2025 | Rayaldee |
| Ardelyx, INC. | $183.98 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.91 | 2024-2025 | Jardiance |
| Astrazeneca Uk Limited | $135.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $85.58 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $79.17 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $70.19 | 2020-2025 | Terlivaz |
| Akebia Therapeutics INC | $66.83 | 2020-2022 | |
| Glaxosmithkline, LLC. | $66.36 | 2022-2025 | Benlysta |
| Vertex Pharmaceuticals Incorporated | $55.92 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.96 | 2025 | |
| Cormedix INC. | $35.95 | 2024 | Defencath |
| Alexion Pharmaceuticals, INC. | $33.29 | 2019 | |
| Merck Sharp & Dohme LLC | $28.61 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $25.12 | 2019-2020 | |
| Daiichi Sankyo INC. | $17.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Polack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.